SCHEMBL1367702

SCHEMBL1367702

O=C(NCCc1ccc(Cl)cc1)c1ccc(CBr)cc1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.75
RAB9A P51151 5/20 0.75
CYP2D6 P10635 2/20 0.75
GAA P10253 2/20 0.75
SMN1; SMN2 Q16637 2/20 0.75
MAPT P10636 2/20 0.75
CYP1A2 P05177 2/20 0.75
CYP2C19 P33261 1/20 0.75
GFER P55789 1/20 0.75
MCHR1 Q99705 4/20 0.68
KMT2A Q03164 3/20 0.62
MEN1 O00255 2/20 0.62
CHRM1 P11229 1/20 0.60
HTR2A P28223 1/20 0.60
ALDH1A1 P00352 1/20 0.59
FABP2 P12104 1/20 0.59
PPARG P37231 1/20 0.59
PPARD Q03181 1/20 0.59
PPARA Q07869 1/20 0.59
TSHR P16473 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27842419 0.91 NPC1 (0.75) NPC1RAB9ACYP2D6GAASMN1; SMN2
SCHEMBL8668493 0.86 NPC1 (1.00) NPC1RAB9ACYP2D6GAASMN1; SMN2
SCHEMBL1368482 0.86 NPC1 (1.00) NPC1RAB9ACYP2D6GAASMN1; SMN2
SCHEMBL1570073 0.84 NPC1 (0.75) NPC1RAB9ACYP2D6GAASMN1; SMN2
SCHEMBL2987921 0.84 NPC1 (0.75) NPC1RAB9ACYP2D6GAASMN1; SMN2
SCHEMBL96062 0.84 NPC1 (0.75) NPC1RAB9ACYP2D6GAASMN1; SMN2
SCHEMBL1922930 0.84 RAB9A (0.74) NPC1RAB9ACYP2D6GAASMN1; SMN2
SCHEMBL28551980 0.84 RAB9A (0.74) NPC1RAB9ACYP2D6GAASMN1; SMN2
SCHEMBL11486928 0.83 NPC1 (0.73) NPC1RAB9ACYP2D6GAASMN1; SMN2
SCHEMBL1367243 0.83 NPC1 (0.73) NPC1RAB9ACYP2D6GAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461329-B2 Isoquinoline derivative TAISHO PHARMACEUTICAL CO., LTD. (JP) 2013-06-11 US disclosed
US-20110288293-A1 ISOQUINOLINE DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2011-11-24 US disclosed
EP-2377851-A1 ISOQUINOLINE DERIVATIVE Taisho Pharmaceutical Co., Ltd. (JP) 2011-10-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110288293-A1 ISOQUINOLINE DERIVATIVE HRH1, HRH2, HRH4 NPC1 161/4885RAB9A 1548/4885CYP2D6 2247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.